Detalhe da pesquisa
1.
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
Diabetologia
; 62(6): 948-958, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30953107
2.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Circulation
; 137(4): 338-350, 2018 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133605
3.
PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS).
Circulation
; 137(12): 1260-1269, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29146683
4.
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
J Hepatol
; 70(3): 483-493, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30414864
5.
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
Arterioscler Thromb Vasc Biol
; 38(7): 1644-1655, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880491
6.
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Eur Heart J
; 39(27): 2577-2585, 2018 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29566128
7.
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.
Circulation
; 135(19): 1819-1831, 2017 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28249876
8.
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
Circulation
; 135(4): 338-351, 2017 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27941065
9.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Lancet
; 390(10106): 1962-1971, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28859947
10.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
N Engl J Med
; 372(16): 1500-9, 2015 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25773607
11.
Evolocumab: Considerations for the Management of Hyperlipidemia.
Curr Atheroscler Rep
; 20(4): 17, 2018 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29511875
12.
Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.
Cardiovasc Drugs Ther
; 32(4): 365-372, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30073585
13.
Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.
J Pharmacokinet Pharmacodyn
; 45(3): 505-522, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29736889
14.
Effect of evolocumab on cholesterol synthesis and absorption.
J Lipid Res
; 57(12): 2217-2224, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27707817
15.
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
J Lipid Res
; 57(6): 1086-96, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27102113
16.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Lancet
; 385(9965): 331-40, 2015 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25282519
17.
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Am Heart J
; 176: 83-92, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27264224
18.
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA
; 316(22): 2373-2384, 2016 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27846344
19.
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
JAMA
; 315(15): 1580-90, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27039291
20.
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Circulation
; 129(2): 234-43, 2014 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24255061